FarmaKology Newsletter - Issue #26

Dec 10, 2019

Today's Startup

twoXAR

twoXAR is a pharmaceutical company that has built a development portfolio targeting more than 18 different diseases. twoXAR’s unique approach to drug discovery combines steps from the traditional multi-step approach to R&D that severely limits the pace of drug discovery. This novel method – coupled with the company’s proprietary AI-driven platform – enables twoXAR to select a disease and initiate in vivo testing in months, instead of years.

News

Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion

Sanofi and Synthorx, Inc., a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).

Omnicell and Kit Check Partner to Offer Cloud-based Solution for Tracking of Controlled Substances

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, has entered into an agreement with Kit Check™ to offer Bluesight™ for Controlled Substances diversion prevention software, helping customers to gain better visibility of controlled substances across the pharmacy supply chain.

Healx Joins Forces with Boehringer Ingelheim to Discover New Treatment Approaches for Rare Neurological Diseases

Healx Ltd., the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.

WORLD’S FIRST MALE CONTRACEPTIVE INJECTION MAY SOON ARRIVE IN INDIA

The world's first male birth control injection is soon going to be launched by India. It is a long-lasting, non – hormonal contraceptive measure for men which will remain effective for 13 years. It will serve as an alternative to surgical vasectomy.